EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers

Ferenc Török, Sarah Salamon, Nadine J Ortner, Monica L Fernández-Quintero, Jan Matthes iD, Jörg Striessnig iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Ferenc Török und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Calcium Channels, L-Type, Calcium Channel Blockers, Isradipine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Pathogenic gain‐of‐function mutations in Ca v 1.3 L‐type voltage‐gated Ca 2+ ‐channels ( CACNA1D ) cause neurodevelopmental disorders with or without endocrine symptoms. We aimed to confirm a pathogenic gain‐of function phenotype of CACNA1D de novo missense mutations A749T and L271H, and investigated the molecular mechanism causing their enhanced sensitivity for the Ca 2+ ‐channel blocker isradipine, a potential therapeutic for affected patients. Experimental Approach Wildtype and mutant channels were expressed in tsA‐201 cells and their gating analysed using whole‐cell and single‐channel patch‐clamp recordings. The voltage‐dependence of isradipine action was quantified using protocols inducing variable fractions of inactivated channels. The molecular basis for altered channel gating in the mutants was investigated using in silico modelling and molecular dynamics simulations. Key Results Both mutations were confirmed pathogenic due to characteristic shifts of voltage‐dependent activation and inactivation towards negative potentials (~20 mV). At negative holding potentials both mutations showed significantly higher isradipine sensitivity compared to wildtype. The affinity for wildtype and mutant channels increased with channel inactivation as predicted by the modulated receptor hypothesis (30‐ to 40‐fold). The IC 50 was indistinguishable for wildtype and mutants when >50% of channels were inactivated. Conclusions and Implications Mutations A749T and L271H induce pathogenic gating changes. Like wildtype, isradipine inhibition is strongly voltage‐dependent. Our data explains their apparent higher drug sensitivity at a given negative voltage by the availability of more inactivated channels due to their more negative inactivation voltage range. Low nanomolar isradipine concentrations will only inhibit Ca v 1.3 channels in neurons during prolonged depolarized states without selectivity for mutant channels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium Channels, L-TypeCalcium Channel BlockersIsradipineHumansDihydropyridinesDose-Response Relationship, DrugMutation, MissenseMolecular Dynamics Simulation

Stichwörter der Autor:innen

CACNA1Dchannelopathiesgain‐of‐function mutationsisradipinevoltage‐gated calcium channels

Substanzen

Calcium Channels, L-TypeCalcium Channel BlockersCACNA1D protein, humanIsradipineDihydropyridines

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
  • Center of Pharmacology, Institute II, University of Cologne, Cologne, Germany.
  • Department of General, Inorganic and Theoretical Chemistry, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Jan Matthes, Jörg Striessnig

Förderung

  • H2020 Marie Skłodowska-Curie Actions
  • Austrian Science Fund

Zitieren

APA

Török, F., Salamon, S., Ortner, N. J., Fernández-Quintero, M. L., Matthes, J., & Striessnig, J. (2025). Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers. British Journal of Pharmacology. https://doi.org/10.1111/bph.17357

Vancouver

Török F, Salamon S, Ortner NJ, Fernández-Quintero ML, Matthes J, Striessnig J. Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers. British Journal of Pharmacology. 2025. doi:10.1111/bph.17357

BibTeX
@article{Trk2025,
  author = {Török, Ferenc and Salamon, Sarah and Ortner, Nadine J and Fernández-Quintero, Monica L and Matthes, Jan and Striessnig, Jörg},
  title = {Inactivation induced by pathogenic Ca v 1.3 L‐type Ca 2+ ‐channel variants enhances sensitivity for dihydropyridine Ca 2+ channel blockers},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17357}
}
Kostenlos starten →